(KRS 0000769049, NIP ) is a Polish company. operates in: Manufacture of basic pharmaceutical products (PKD 21.10.Z). Industry: Pharmaceuticals. The company has been listed in the National Court Register since January 31, 2019. 's most recently reported net revenue was 0 PLN for 2026.
Negative equity
Negative equity in 6 of 7 available reporting years.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile
Identity
- Name
- Legal form
- Founded
- January 31, 2019
- Registry status as of
- July 13, 2026
- Latest entry
- July 13, 2026
Activities
Other activities
Address and contact
- Address
- Voivodeship
- District
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile
Credibility rating
21.8 / 100
Poor credibility
Insolvency risk
High
Significant formal threat
Closure risk
37
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/7 yrs
Board changes
3
3/7 yrs
PKD changes
0
0/7 yrs
Name changes
0
0/7 yrs
Data from 7 years of registry activity.
Credibility history
Payment reliability score from 2020–2026
Current: E (22/100)
Trend: improving (+8.1 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2020–2026
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status
Founded
January 31, 2019
7 years in operation
Legal form
N/A
Registry: RejP
Headquarters
N/A
Primary PKD
21.10.Z
Manufacture of basic pharmaceutical products
Share capital
N/A
Shareholders
N/A
Board
6 people
Filed years
7 years
2020–2026 · profitable: 0/7
Registry entries
15
latest: July 13, 2026
Risk signals
Revenue
0 PLN
2026
Net profit
-3.2 M PLN
2026
Assets
62.9 K PLN
2026
Equity
-83.2 K PLN
2026
EBITDA
-3.2 M PLN
2026
Public procurement
Trademarks
Reviews
Rate business credibility - .
No ratings
Related articles
News
Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss
Warsaw-based Bioton S.A. (KRS 0000214072) - the only Polish manufacturer of biosynthetic human insulin - closed 2025 with revenue of PLN 235.9 m and EBITDA of PLN 53.82 m (margin 18.72%), but a net loss of around PLN -16.4 m keeps the company in the red. EBITDA improved 76% versus 2024 (PLN 30.6 m), driven by international expansion (Malaysia ~PLN 100 m a year) and a contract to produce the insulin analogue Glargine. Yifan Pharmaceutical controls 31.65% of capital indirectly.
News
Celon Pharma 2025: record PLN 244 m revenue, but net loss deepens to PLN 79.4 m - the 2026 outlook hinges on Salmex registration in China and the GLP-1 programme
Celon Pharma S.A. (KRS 0000437778, Kiełpin/Łomianki) closed 2025 with consolidated revenue of PLN 244.34 m (+17.9% YoY), EBITDA of PLN 21.42 m (+42%) and a deepened net loss of PLN -79.36 m (vs PLN -34.45 m a year earlier). The deeper loss reflects spending on the innovative GLP-1 segment. The generics segment grows (+15.3%) and represents 84.4% of revenue. Salmex registration in China is expected by end-2026. Maciej Wieczorek controls 58.8% of capital and 68.2% of voting rights through Glatton sp. z o.o.
